MediciNova, Inc. Stock price

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.45 USD -1.36% Intraday chart for MediciNova, Inc. +5.07% -3.33%
Sales 2024 * - Sales 2025 * - Capitalization 72.1M
Net income 2024 * -11M Net income 2025 * -11M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-6.39 x
P/E ratio 2025 *
-6.13 x
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.44%
More Fundamentals * Assessed data
Dynamic Chart
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China CI
Top Premarket Gainers MT
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe CI
Sector Update: Health Care Stocks Lean Down Premarket Monday MT
MediciNova Says Glioblastoma Phase 2 Trial of Therapy Combo Showed Progression-Free Survival of 44% at Six Months MT
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada CI
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary MT
Sector Update: Health Care Stocks Gain Premarket Thursday MT
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study MT
More news
1 day+8.09%
1 week+6.52%
Current month+8.89%
1 month+13.95%
3 months+1.38%
6 months-29.67%
Current year-2.00%
More quotes
1 week
1.36
Extreme 1.36
1.47
1 month
1.30
Extreme 1.3
1.47
Current year
1.26
Extreme 1.26
1.70
1 year
1.26
Extreme 1.26
2.66
3 years
1.26
Extreme 1.26
5.28
5 years
1.26
Extreme 1.26
13.37
10 years
1.26
Extreme 1.26
14.50
More quotes
Managers TitleAgeSince
Founder 74 00-09-25
Director of Finance/CFO 47 22-06-15
Chief Tech/Sci/R&D Officer 58 09-12-31
Members of the board TitleAgeSince
Director/Board Member 67 04-08-31
Founder 74 00-09-25
Director/Board Member 66 20-10-19
More insiders
Date Price Change Volume
24-03-28 1.45 -1.36% 62 995
24-03-27 1.47 +8.09% 264,298
24-03-26 1.36 -1.45% 67,515
24-03-25 1.38 -0.72% 23,572
24-03-22 1.39 -2.11% 31,908

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.47 USD
Average target price
17 USD
Spread / Average Target
+1,056.46%
Consensus
  1. Stock
  2. Equities
  3. Stock MediciNova, Inc. - Nasdaq